Literature DB >> 16863916

Developmental stage-specific shift in responsiveness to chemokines during human B-cell development.

Marek Honczarenko1, Aleksandra M Glodek, Marcin Swierkowski, Il-Kang Na, Leslie E Silberstein.   

Abstract

OBJECTIVES: To better understand the role of chemokines during human B-cell development in bone marrow.
METHODS: Differentiation stage-specific B cells (pro-B, pre-B, immature, and mature) were analyzed for chemokine receptor expression and for migration to corresponding ligands. We also hypothesized that inflammatory conditions may cause the upregulation of certain chemokine receptors on early B cells, rendering them sensitive to extramedullary chemotactic cues. To test this hypothesis, we used human pre-B 697 cells to investigate whether various inflammatory agents could modify chemokine receptor expression and function.
RESULTS: Chemotaxis to CXCL12 was observed for all B cell subsets. However, chemotactic responses to CCL19, CCL21, CXCL13, and CCL20 were limited to late-stage, IgM+ bone marrow B cells (immature B and mature B). Chemotactic responses to corresponding ligands correlated with the pattern of chemokine receptor expression. The expression of CCR7, however, was low on early (pro-B and pre-B) B cells and did not induce chemotaxis. Interestingly, both CCL19 and CCL21 could trigger ERK1/2 phosphorylation in early B cells. Exposure of pre-B 697 cells to TNF-alpha upregulated CCR7 and CXCR5 expression, whereas it had no effect on CCR6 surface expression. Correspondingly, TNF-alpha-stimulated pre-B cells chemotaxed towards CCL19 and CXCL13, in contrast to non-TNF-alpha-stimulated controls.
CONCLUSION: We postulate that CXCR5, CCR7, and CCR6 participate in bone marrow trafficking and/or bone marrow egress of late-stage B cells under steady-state conditions, whereas inflammation-induced expression of CCR7 and CXCR5 may facilitate early B-cell emigration out of the bone marrow and their positioning in secondary lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16863916     DOI: 10.1016/j.exphem.2006.05.013

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

1.  CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Authors:  Marion Leick; Julie Catusse; Marie Follo; Robert J Nibbs; Tanja N Hartmann; Hendrik Veelken; Meike Burger
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

2.  Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.

Authors:  Julie Catusse; Marion Leick; Mareike Groch; David J Clark; Maike V Buchner; Katja Zirlik; Meike Burger
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

3.  Coexpression of CCR7 and CXCR4 During B Cell Development Controls CXCR4 Responsiveness and Bone Marrow Homing.

Authors:  Saria Mcheik; Nils Van Eeckhout; Cédric De Poorter; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

4.  A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.

Authors:  Yue-Miao Zhang; Xing-Zi Liu; Xu-Jie Zhou; Li-Jun Liu; Su-Fang Shi; Ping Hou; Ji-Cheng Lv; Hong Zhang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 5.  Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system.

Authors:  Denitsa Docheva; Cvetan Popov; Wolf Mutschler; Matthias Schieker
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.